title: [Present status and perspective of targeted therapy for B-cell lymphoma].
authors: Ken
authors: K
authors: Ohmachi
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001897:Boronic Acids; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D055808:Drug Discovery / Q000639:trends*; D005419:Flavonoids; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids; D000077269:Lenalidomide; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000639:trends*; D010880:Piperidines; D011480:Protease Inhibitors; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D064546:Protein Kinase C beta; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011719:Pyrazines; D000069283:Rituximab; D013792:Thalidomide / Q000031:analogs & derivatives; D000077337:Vorinostat
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001897:Boronic Acids; D005419:Flavonoids; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D010880:Piperidines; D011480:Protease Inhibitors; D011719:Pyrazines; C077990:alvocidib; D000069283:Rituximab; D013792:Thalidomide; D000077337:Vorinostat; D000069286:Bortezomib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D000077269:Lenalidomide